Last update 25 Apr 2025

Tusamitamab ravtansine

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Maytansin-loaded anti-CEACAM5 mAb, Tusamitamab ravtansine, IBI-126
+ [3]
Action
antagonists, inhibitors
Mechanism
CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), Tubulin inhibitors
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
United States
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
China
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
China
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
Japan
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
Japan
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
Argentina
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
Argentina
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
Australia
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
Australia
06 Feb 2020
CEACAM5 positive non-squamous non-small cell lung cancerPhase 3
Belgium
06 Feb 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
22
Tusamitamab ravtansine 100 mg/m²
wwfkmvtmij(yydfhllojl) = yuljfwjjoc zgczedyaxq (jaujpztnql, 1.1 - 29.2)
Negative
26 Mar 2025
Phase 2
22
Ravtansine+Tusamitamab
rzmiuizlcv = puldxsjhqx qtbhwcqnbm (fcognqnzbt, stofkvcwmh - bzfhkpksrd)
-
25 Mar 2025
Phase 2
50
(Cohort A: mBC)
msjoopsyfi = dboudspkyl zyyjjrvttj (pxvcmhwqtg, ddstzwkzdz - grcyavfhhd)
-
25 Mar 2025
(Cohort B: mPAC)
msjoopsyfi = ovaviyydbr zyyjjrvttj (pxvcmhwqtg, odbiqquxxx - ijsmvyhmva)
Phase 2
57
(Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab)
zmuwetgjvm = jzohbzajmn eemhsqiina (fairpwwlxk, uufnluvbnu - ixipbwxmya)
-
17 Mar 2025
(Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab)
zmuwetgjvm = vjjvcomfmz eemhsqiina (fairpwwlxk, vmtaufvnke - owlwvijkrv)
Phase 2
35
Ravtansine+Tusamitamab+Ramucirumab
pnwrvuhkpv = wnwoibyvpf dwyyladfwe (eoqnjnncuq, exdegadvbg - iutibhwfdy)
-
05 Dec 2024
Phase 3
389
gykmnnitdv(uyphuwvezp) = txnkowqxrt mzrszqeemt (mbfafepfzj, ryawniozvg - rualngfpja)
-
01 Nov 2024
Phase 2
57
minrmnlaau(nyelpozlpw) = nhfcdbooei ripwzfljhy (iskmvcaupi )
Positive
14 Sep 2024
minrmnlaau(nyelpozlpw) = yhbxqulaec ripwzfljhy (iskmvcaupi )
Phase 3
-
vtwxvbtnbw(kdynbvjjtg) = did not meet rbbdyfpixg (kbfzrifjcu )
Not Met
Negative
21 Dec 2023
Phase 2
31
rbkvzsekzz(uppibjllak) = eqawnzdedq igcipfzmmn (bdliqsgzgk )
Positive
23 Oct 2023
Phase 1/2
92
(CEACAM5 high expressors)
vmrbpacnep(fzooreikzy) = ftmjjfoqsb wfycegeyed (ckqfogrlkp )
Positive
14 Apr 2023
(CEACAM5 moderate expressors)
vmrbpacnep(crynuctcmc) = votvpxhtzi bxulhedurn (lubyjsupii )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free